Back
There's a reproducibility
crisis in life science.
Here's how we're helping to beat it.
A heartbreaking amount of time, resources, and hard work gets
thrown away on irreproducible science. $28 billion gets wasted
on unrepeatable preclinical research every year in the USA alone1
– that’s more than half the National Institutes of Health’s annual
medical research budget.
That’s why we’re continually improving the quality of
our antibody range to ensure the highest possible
performance and reliability, and keep researchers
moving forward. Since 2010, we’ve withdrawn over
60,000 products that haven’t kept up with our rising
standards.
“What’s great is that abcam has many recombinant antibodies validated by knockout, which gives us a lot of confidence in the results.”
Dr Graham Heieis, Leiden Medical Center
“Our mission is to help scientists achieve their discoveries faster, and providing reagents that work the first time, every time, is key to fulfilling this goal.”
Dr Alejandra Solache, Abcam’s Senior Vice President of Research and Development
References
1. Freedman, L., Cockburn, I. & Simcoe, T. The Economics of Reproducibility in
Preclinical Research. PLOS Biology 13, e1002165 (2015).
.
2. Baker, M. 1,500 scientists lift the lid on reproducibility. Nature 533, 452–454
(2016).